Syntermed announces its appointment by Lantheus Holdings, Inc. We accelerated our growth. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; TechneLite ® (Technetium Tc99m Generator), a. m. BEDFORD, Mass. Product Uses: diagnostic radiopharmaceutical . Lantheus’ product, PYLARIFY ® (piflufolastat F 18) injection, is a radioactive diagnostic agent indicated for PET imaging of PSMA positive lesions in men with prostate cancer: with suspected. PDF Version. U. INDICATION. Lantheus has offices in Massachusetts, New Jersey, Canada and Sweden. DEFINITY closed out 2022 with $245 million of net sales, an increase of 5. In the U. S. Clinical correlation, which may include histopathological evaluation of the suspected prostate cancer site, is recommended. February 16, 2023 at 8:30 AM EST. PYLARIFY is used along with positron emission tomography (PET) imaging for men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer,. Under. 1% over the. In the second full quarter for both products in the market, PYLARIFY -- Lantheus -- reported $35. 7 million for the second quarter 2022, representing an increase of 121. On the call, management stated that PYLARIFY and DEFINITY enabled Lantheus to invest in its business to continue to expand its portfolio of commercial and clinical-stage radiopharmaceutical assets. Lantheus Announces Presentations Featuring PYLARIFY AI™ at the 2023 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting. Customer Support at 1-800-964-0446 M-F 8:30 am-8:00 pm EST, or email cspyl@lantheus. Each milliliter contains 37 to 2,960 MBq (1 to 80 mCi) piflufolastat F 18 with ≤0. 28, 2021 2:48 PM ET Lantheus Holdings, Inc. Sanchez-Crespo A. Food and Drug Administration (May 2021) as the first and only commercially available, approved PSMA PET imaging agent for prostate cancer. Lantheus presented study results providing independent validation of PYLARIFY AI™, the Company’s artificial intelligence (AI) platform developed to assist in standardized quantification of. Lantheus Announces Presentations Featuring PYLARIFY AI™ at the 2023 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting June 12,. Lantheus Reports First Quarter 2023 Financial Results. S. 12. Lantheus Holdings (LNTH) announced Thursday that it would discontinue production and promotion of its FDA-approved radiotherapeutic Azedra. PYLARIFY is the first and only commercially available, FDA-approved PSMA-targeted PET imaging agent for prostate cancer NORTH BILLERICA, Mass. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving. Lastly, net cash used in operating activities was $32. Lantheus to Host Third Quarter 2023 Earnings Conference Call and Webcast on November 2, 2023, at 8:00 a. Lantheus provides a broad portfolio of products, including PYLARIFY ® (Piflufolastat F18), a PSMA PET imaging agent for the. PYLARIFY –Prostate Cancer Franchise Overview Paul Blanchfield, Chief Commercial Officer Etienne Montagut, Chief Business Officer Aseem Anand, VP of Digital Solutions PYLARIFY Key Opinion Leader Panel Moderator: Bela Denes, M. , a Lantheus company . NORTH BILLERICA, Mass. North Billerica, MA: Progenics Pharmaceuticals, Inc. 9% Sodium Chloride Injection, USP. 5 million, representing 61. The company is well-positioned to generate substantial free cash flow The cash flow statement provides a detailed overview of the cash inflows and outflows of a company over a specified period. Today, we put the spotlight on Lantheus Holdings for the first time. 97 for the first quarter of 2022, representing an increase of approximately $0. About Lantheus Holdings, Inc. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging. 47 on an adjusted basis, an increase of 48% over the prior-year quarter. The Company’s third quarter 2023 adjusted fully diluted net income per share, or earnings per share (“EPS”), was $1. 88 and earnings of $1. 6 million for the fourth quarter of 2021, representing an increase of 103. Before that Lantheus, which has operated since the 1950s, relied on established businesses in microbubbles and spect imaging. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, announced it will present the following presentations at. Search Interest 21 people have searched for LNTH on MarketBeat in the last 30 days. “PYLARIFY has the potential to contribute meaningful and actionable information that can be used to personalize treatment plans in men with low PSA levels,” said Dr. On the fourth-quarter 2022 earnings call in February, Lantheus Holdings’ management confirmed that it has been registering a robust uptick in sales of its PYLARIFY, an F 18-labelled PSMA. PYLARIFY (piflufolastat F 18) injection (also known as 18 F-DCFPyL or PyL) is a fluorinated small molecule PSMA-targeted PET imaging agent that enables visualization of lymph nodes, bone and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. 89 for the second quarter of 2022, representing an increase of approximately $0. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging. m. 48 from the prior year period. and EXINI Diagnostics AB. June 12, 2023 at 8:30 AM EDT. “Today marks an important day for Lantheus and Progenics. PYLARIFY AI is an FDA-cleared artificial intelligence platform developed to assist in standardized quantification of PSMA PET/CT scans. The Company’s third quarter 2023 adjusted fully diluted net income per share, or earnings per share (“EPS”), was $1. Diagnostic performance of 18 F-DCFPyL-PET/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study. Indication PYLARIFY ® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen. Those with suspected metastasis who are candidates for initial definitive therapy or those with suspected recurrence based on elevated. 9% Sodium Chloride Injection, USP. , a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and. Mid-cap Lantheus Holdings has been on a revenue growth spurt boosted by a new product called Pylarify, which helps detect prostate cancer in an imaging test. The Company’s worldwide revenue for the third quarter of 2022 totaled $239. Nov 2014 - Sep 2017 2 years 11 months. LNTH earnings call for the period ending June 30, 2021. 4 million in revenue, up 25% year over year, and a net loss of $11. For information about ordering PYLARIFY® for your imaging site, and how to get started, contact PYLARIFY®. US Customer Service/Order PYLARIFY®. PYLARIFY® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. , June 12, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings , Inc. disease. For more information, visit Contacts: Mark Kinarney Vice President, Investor Relations 978-671-8842 [email protected] Anne Heino: Thank you, Mark, and good morning to everyone. In May 2021, the FDA approved the PSMA PET imaging agent piflufolastat F 18 (Pylarify) for identifying suspected metastasis or recurrence of prostate cancer. 0% from the prior year period. 2. 8% from the prior year period. PYLARIFY may be diluted with 0. , Sept. PDF. Lantheus Reports Second Quarter 2023 Financial Results. Food and Drug Administration in May 2021. 25 reported a year ago. The stock has been a big winner in 2022 thanks to the impressive growth racked up by recently launched imaging agent Pylarify. OSPREY was a robust, prospective, multicenter, phase 2/3 clinical trial of 385 men with either high-risk prostate cancer (Cohort A; n=268) or radiologic evidence of recurrence (Cohort B; n=117) OSPREY assessed the sensitivity, specificity, PPV, and NPV in pelvic lymph nodes for PYLARIFY® PET/CT. 28 May, 2021, 07:00 ET. PYLARIFY AI is an FDA-cleared artificial intelligence platform developed to assist in standardized quantification of PSMA PET/CT scans. Lantheus Holdings, Inc. Global Data 3rd line treatment for metastatic castration-resistant prostate cancer (“mCRPC”), Lantheus primary market research informing imaging procedures performed during radioligand treatment. DULLES, Va. 肿瘤学放射性药物 （帮助医疗保健专业人员发现、治疗和跟踪癌症的诊断和治疗方法）： ·PYLARIFY（也被称为Piflufolastat F-18、18F-DCFPyL或PyL）是一. 18F-DCFPyL is now the first. Lantheus (LNTH) stock rose ~17% on Thursday after Q4 results beat estimates and the FY23 outlook was placed above expectations. S. S. PYLARIFY (piflufolastat F18) injection. #Lantheus was thrilled to be a Gold Sponsor of the 16th Clinical Trials on Alzheimer’s Disease conference (CTAD), which took place from Oct 24-27 in Boston! It was a wonderful opportunity to connect with our partners in the industry and academia who are using our investigational Tau PET imaging agent in their clinical trials. PYLARIFY is used along with positron emission tomography (PET) imaging for men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. is the parent company of Lantheus Medical Imaging, Inc. October 19, 2023. 50. BEDFORD, Mass. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; TechneLite ® (Technetium Tc99m Generator), a. Lantheus Announces Top Rated Oral Presentation Featuring PYLARIFY AI™ at the 2023 European Association of Nuclear Medicine (EANM) Annual Meeting. PYLARIFY, approved by the FDA in May 2021, is the first commercially and widely available prostate-specific membrane antigen (PSMA) PET imaging agent. On-site plant will produce. “2022 was an outstanding year for Lantheus, led by the success of PYLARIFY and expansion of our Radiopharmaceutical Oncology pipeline. The Lantheus Protocol: Pylarify Growth May Slow The outlook from management for Pylarify growth was not what analysts -- who are are modeling this product out 2-3 years -- were expecting. Eastern Time. US Customer Service/Order PYLARIFY®. The company reported Q4 adjusted EPS of $1. The Lantheus Protocol: Pylarify Growth May Slow. Lantheus Announces Presentations Featuring PYLARIFY® (Piflufolastat F18), PYLARIFY AI™ and NM-01 (PD-L1 Imaging) at the 2022 Society for Nuclear. Pylarify (piflufolastat), which was approved in 2021 by the Food and Drug Administration, is a. Lantheus receives US FDA approval of PYLARIFY (piflufolistat F 18) injection, the first and only commercially available PSMA PET imaging agent for prostate cancer. 0. BEDFORD, Mass. Novartis will include PYLARIFY® (piflufolastat F18) in their clinical trials for Pluvicto™ (lutetium Lu. • Assay the dose in a suitable dose calibrator prior to administration. This agent is similar to the Gallium-68 PSMA-11 agent which was approved in December 2020, except that it can be produced in much greater quantities and distrMarketBeat has tracked 5 news articles for Lantheus this week, compared to 5 articles on an average week. PYLARIFY® IS UNIQUE. with suspected recurrence based on. PYLARIFY uptake is not specific for prostate cancer and may occur with other types of cancer as well as non-malignant processes and in normal tissues. --(BUSINESS WIRE)--Dec. Outside U. 1% over the. “We successfully launched PYLARIFY, which we believe is the best-in-class PSMA PET imaging agent for prostate cancer, maintained our revenue growth and. UPDATE: On March 23, 2022, the Food and Drug Administration (FDA) approved Lu177-PSMA-617 (Pluvicto) to treat some adults with metastatic prostate cancer. Lantheus market research and analysis with ordering physicians, NCCN, ACS, UpToDate, SEER. We obtained FDA approval for and successfully launched PYLARIFY®Lantheus will fund the all-cash license of exclusive worldwide rights, excluding certain territories 1, for PNT2002 and PNT2003 with cash on Lantheus’ balance sheet and committed financing. 7% year-over-year growth and approximately 8% sequential growth from the first quarter of 2023. patents apply to our products: DEFINITY ® /DEFINITY. 3M as the prostate cancer diagnostic agent Pylarify added $143. The company's. The stock has been outperforming its index, the S&P Midcap 400, by a wide margin. Lantheus presented study results providing independent validation of PYLARIFY AI , the Company s artificial intelligence (AI) platform developed to assist in standardized quantification of PSMA PET/CT scans. “Lantheus is leading the way in harnessing the power of AI and machine learning technologies, together with our game-changing PSMA-targeted PET imaging agent PYLARIFY, to potentially transform. Pylarify. The Company’s worldwide revenue for the second quarter of 2022 totaled $223. 37, surpassing the consensus of $0. Lantheus Holdings, inc ( LNTH 2. On the call, management stated that PYLARIFY and DEFINITY enabled Lantheus to invest in its business to continue to expand its portfolio of commercial and clinical-stage radiopharmaceutical assets. Lantheus Announces Presentations Featuring PYLARIFY AI™ at the 2023 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting. The PyLAM is the primary customer facing Lantheus Holdings professional tasked with education of the Prostate Cancer medical referral community on PyLARIFY and the cultivation of productive customer relationships to include HCPs, Advanced Practice Providers, Nurses, Pharmacists, Department Administrators and other key medical and. S. BEDFORD, Mass. , May 28, 2021 /PRNewswire/ -- SOFIE, an established Radiopharmaceutical Contract Manufacturing Organization and GMP radiopharmacy network, will be commercially. and Progenics Pharmaceuticals, Inc. 7 million in the prior year period ; GAAP fully diluted net income per share of $0. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; PYLARIFY AI™, an artificial intelligence platform that assists in the. Lantheus Holdings, Inc. In the U. PYLARIFY AI™ (aPROMISE) is the only deep learning enabled FDA-cleared medical device software to offer standardized PSMA PET reporting with PYLARIFY AI on PSMA PET/CT images, including those. Read More. Lantheus has been on a revenue growth spurt in recent quarters, boosted by Pylarify. PYLARIFY is the first and only commercially available, FDA-approved PSMA-targeted PET imaging agent for prostate cancer. GAAP net. 1% and 119. For International Transportation. (the Company) (NASDAQ: LNTH), a company committed to“Lantheus is a demonstrated commercial leader in the field of radiopharmaceuticals. 0% from the prior year period. For men with prostate cancer,. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider committed to innovative imaging diagnostics. 48 from the prior year period. PYLARIFY AI™ is intended to be used by healthcare professionals and researchers for acceptance, transfer, storage, image display, manipulation, quantification and reporting of digital medical images. PYLARIFY AI is an FDA-cleared medical device software and is commercially available in the United States. Eastern, Monday - Friday © 2023 Lantheus. m. Lantheus Presents Results from a PYLARIFY AI™ Study at the American Urological Association (AUA) Annual Meeting. For information about ordering PYLARIFY® for your imaging site, and how to get started, contact PYLARIFY®. For information about ordering PYLARIFY® for your imaging site, and how to get started, contact PYLARIFY®. PYLARIFY success leads to maximum payment in first yearBEDFORD, Mass. The PyLAM is the primary customer facing Lantheus Holdings professional tasked with education of the Prostate Cancer medical referral community on PyLARIFY and the cultivation of productive customer relationships to include HCPs, Advanced Practice Providers, Nurses, Pharmacists, Department Administrators and other key medical and. Attend the UAB Nuclear Medicine and Molecular Therapy Intensive, offered in collaboration with SNMMI-TS, Monday, April 29. Pylarify is the largest growth driver for the company as it comprised 65% of. Lantheus también está trabajando en el desarrollo de productos para otros tipos de cáncer, como los tumores neuroendocrinos, y en el diagnóstico y estadificación de la. 01. D. Lastly, net cash provided by operating activities was $108. News release. 2% for the week as of Friday afternoon,. PYLARIFY AI is an FDA-cleared medical device software and is commercially available in the United States. NORTH BILLERICA, Mass. TechneLite net revenue was $24. com. (the Company) (NASDAQ: LNTH), a company committed to“PYLARIFY AI has the potential to contribute meaningful insights to inform treatment selection and monitoring in prostate cancer. Indication PYLARIFY ® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen. LinkedIn. Heino , President and Chief Executive Officer of Lantheus . "2022 was an outstanding year for Lantheus, led by the success of PYLARIFY and the. and EXINI Diagnostics AB and anWorldwide revenue of $223. Morris MJ, Rowe SP, Gorin MA, et al. • Dispose of any unused PYLARIFY in compliance with applicable regulations. According to Evaluate, doctors prescribing Pluvicto are abandoning Novartis' own. 3% over the prior year. . Shares of Lantheus Holdings (LNTH-0. TechneLite net revenue was $24. 4% from the prior year period ; GAAP net income of $61. It is worth mentioning that PYLARIFY is an F 18-labelled PSMA-targeted. and EXINI Diagnostics AB. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; TechneLite ® (Technetium Tc99m Generator), a. EMERGENCY PHONE: CHEMTREC 1-800-424-9300. Worldwide revenue of $263. CAS Number: 1423758-00-2. “In addition to FDA approval, inclusion in the guidelines. “PYLARIFY has the potential to contribute meaningful and actionable information that can be used to personalize treatment plans in men with low PSA levels,” said Dr. 50 from the prior year period. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable. Product Uses . (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, announced PYLARIFY AI data will be presented at the. ” Prostate cancer is a common and usually slow-growing cancer. 2 million, or $0. 9 mg ethanol in 0. Retrospective analysis demonstrates reliability of PSMA scan indices as response-imaging biomarker to androgen therapy in prostate cancer. S. These developments underscore Lantheus’ efforts to establish PYLARIFY as a PSMA PET imaging agent of choice in the U. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions. – Paul Blanchfield, Chief Commercial Officer at Lantheus. In 2022, more than 100,000 patient scans using PSMA PET with PYLARIFY were performed. Lantheus expects their fully diluted adjusted earnings per share to be between $0. Hours: 8:30 am to 8:00 pm ET, Monday to Friday. His confidence is backed by Lantheus’s Q3 results which exceeded Street expectations, largely due to the continued strength of their product, Pylarify, and their Precision Diagnostics segment. Phone: 1-800-964-0446. Phone: 1-800-964-0446. For more information, visit Contacts: Mark Kinarney Vice President, Investor Relations 978-671-8842 ir@lantheus. “Being selected by Lantheus to partner to administer the first dose of PYLARIFY is an honor, and it’s humbling to know that GenesisCare will be potentially helping men with prostate cancer, while improving access to high-quality care for our patients. C. NORTH BILLERICA, Mass. Lantheus Holdings, Inc. with suspected recurrence based on elevated serum levels of prostate-specific antigen (PSA) level. In May 2021, Lantheus won Food and Drug Administration approval for its newest growth driver, Pylarify. com. FDA Approval of PYLARIFY® (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA PET. PYLARIFY was approved by the U. A sample CMS-1500 claim form for billing PYLARIFY® is provided below. The Company’s first quarter 2023 adjusted fully diluted net income per share, or earnings per share (“EPS”), was $1. S. But most. Billerica, MA 01862 . Lantheus experienced tremendous growth in last 2 years thanks to the approval of a new imaging agent called PYLARIFY. with suspected recurrence based on elevated serum levels of prostate-specific antigen (PSA) level. 45%. 7 million for the second quarter 2023, representing an increase of 43. “The data we presented at ASCO GU emphasize the clinical utility of piflufolastat F 18 to. Visit Investor Site. com. The collaboration with Novartis directly aligns with Lantheus’ strategy to advance cancer precision medicine by enabling partners to use PYLARIFY in prostate cancer therapeutic. S. 3 million for the third quarter 2022, representing an increase of 134. Piflufolastat F 18 was approved in the USA on 27 May 2021 for PET of PSMA. Worldwide revenue of $321. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; TechneLite ® (Technetium Tc99m Generator), a. 1 million for the second quarter 2023, compared to GAAP net income of $43. Lantheus Original Approval date: May 26, 2021. Before that Lantheus, which has operated since the 1950s, relied on established businesses in microbubbles and spect imaging. Lantheus Holdings, Inc. 2021 was a year of significant achievements for Lantheus. We executed on our strategy to accelerate growth, diversify our commercial and development portfolios, and position Lantheus as a category leader in the markets we serve. FDA Approval of PYLARIFY® (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA PET Imaging Agent for. ir@lantheus. About Lantheus With more than 65 years of experience in delivering life. Leading the way for Lantheus is PYLARIFY, which delivered sales of $210. , Progenics Pharmaceuticals, Inc. Data presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium Demonstrate Potential Benefits of. 3 million for the third quarter 2022, representing an increase of 134. , VP, Medical Affairs E. 9% Sodium Chloride Injection, USP. PYLARIFY® (piflufolastat F18) injection was the first commercially available PSMA-targeted PET imaging agent for prostate cancerNORTH BILLERICA, Mass. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging. Melissa Downs Senior Director, Corporate Communications 646. BEDFORD, Mass. Hours: 8:30 am to 8:00 pm ET, Monday to Friday. We accelerated our growth, diversified our portfolio, and delivered record revenues and profits which created additional free cash flows,” said Mary Anne Heino , President and Chief Executive Officer of. com. The program is available to HCPs who have completed the PYLARIFY® Reader Training. Además del éxito de PYLARIFY, Lantheus también destacó oportunidades de crecimiento en el tratamiento del cáncer de próstata con su producto PNT2002. S. S. PYLARIFY may be diluted with 0. 3 million, compared with $102. 9% over the prior year periods. North Billerica, MA: Progenics Pharmaceuticals, Inc. NEW YORK, Feb. 9, 2020-- Lantheus Holdings, Inc. Melissa Downs Senior Director, Corporate Communications 646. 3. The device provides general. S. 31 Mar, 2022, 09:00 ET. Lantheus Holdings, Inc. PYLARIFY® [package insert]. S. Post Administration Instructions • Follow the PYLARIFY injection with an intravenous flush of 0. prostate cancer community and are likely to have contributed to the top. is the parent company of Lantheus Medical Imaging, Inc. In hindsight it appears that the sellside failed to appreciate Pylarify's potential. About Lantheus With more than 65 years of experience in delivering life. PYLARIFY AI is an FDA-cleared artificial intelligence platform developed to assist in standardized quantification of PSMA PET/CT scans. Lantheus Announces Top Rated Oral Presentation Featuring PYLARIFY AI at the 2023 European Association of Nuclear Medicine (EANM) Annual Meeting September 1, 2023 at 8:30 AM EDT BEDFORD, Mass. As a result of the net sales generated by PYLARIFY in 2022, the maximum aggregate cash payment of $99. The Lantheus Protocol: Pylarify Growth May Slow The outlook from management for Pylarify growth was not what analysts -- who are are modeling this product out 2-3 years -- were expecting. by year endNORTH BILLERICA, Mass. In the last reported quarter, the company’s earnings of 97 cents per share. Nov 6, 2021, 2:00 p. 1 million for the second quarter of 2021, representing an increase of 121. 36%) Q3 2021 Earnings Call. “Lantheus is leading the way in harnessing the power of AI and machine learning technologies, together with our game-changing PSMA-targeted PET imaging agent PYLARIFY, to potentially transform. The following U. Indication PYLARIFY ® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen. Product Uses . (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes. In the U. Worldwide revenue of $239. Lantheus Holdings, Inc. COMPANY IDENTIFICATION: Progenics Pharmaceuticals, Inc. PYLARIFY AI™ (aPROMISE) is the only deep learning enabled FDA-cleared medical device software to offer standardized PSMA PET reporting with PYLARIFY AI on PSMA PET/CT images, including those. Lantheus credited the revenue rise from increased sales for its Pylarify PSMA PET imaging agent, used to detect recurrent or metastatic prostate cancer, as well as increased use of its Definity. Melissa Downs. NORTH BILLERICA,. 2 million for the third quarter 2022, compared to GAAP net loss of $13. DEFINITY in our in-house manufacturing facility; (v) our ability to successfully launch PYLARIFY AI as a commercial product; (vi) the continuing impact of the global COVID-19 pandemic on our business, supplyPhysicians and staff can use this resource to streamline access and reimbursement for PYLARIFY® (piflufolastat F 18) injection for appropriate patients. Pylarify (piflufolastat), which was approved in 2021 by the Food and Drug Administration, is a. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging. , a Lantheus company, for positron emission tomography (PET) that targets prostate-specific membrane antigen (PSMA). 5 stocks we like better than LantheusNano-X reported $2. Lantheus presented study results providing independent validation of PYLARIFY AI™, the Company’s artificial intelligence (AI) platform developed to assist in standardized quantification of PSMA PET/CT scans. In. GAAP. This combination forms an innovative company with a diversified diagnostics and therapeutics portfolio,” said Mary Anne Heino, Lantheus President and Chief Executive Officer. 17%. Even if Bracco were to secure 40%+ share in an expanding F-18 PSMA PET imaging market over the next 3 years, the Truist team still thinks Pylarify and Lantheus are undervalued, especially with the. PYLARIFY is a. -1. 6 million to the ante. 8 million, compared to a loss of $21. 7 million for the third quarter 2023. But. Lantheus has multiple products on the market with two standouts driving the most growth with Pylarify and Definity. , June 12, 2023 (GLOBE NEWSWIRE) — Lantheus Holdings, Inc. In the U. 01 µg/mCi of piflufolastat at calibration time and date, and ≤ 78. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative. PYLARIFY seems to be affected by the amount (level) of PSA in your blood. Nominee: Lantheus’ PYLARIFY injection and PYLARIFY AI. Image source: The Motley Fool. (NASDAQ:LNTH) Q3 2023 Earnings Call Transcript November 3, 2023 Operator: Good morning. PYLARIFY® Peer-to-Peer Reader Assistance Program is a complementary program to the PYLARIFY® Reader Training that provides guidance and assistance to healthcare providers on how to accurately read and interpret PYLARIFY® scans. “Lantheus delivered another strong quarter and full year, highlighted by revenue performance which increased 38% and 25%, respectively,” said Mary Anne Heino, President and CEO. "2022 was an outstanding year for Lantheus, led by the success of PYLARIFY and the expansion of our Radiopharmaceutical Oncology pipeline. 8 million for the first quarter 2023, representing an increase of 44. (NASDAQ:NASDAQ:LNTH) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ETCompany ParticipantsMark Kinarney - VP, IRMary. 01, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings , Inc. Our products have practical applications in oncology, cardiology and more. Pylarify is the largest growth driver for the company as it comprised 65% of. For $260m Lantheus secured rights to Point’s two most advanced radioligand therapeutic projects, one of which concerns prostate cancer and hits PSMA – the target for Pylarify and for two Lantheus development-stage therapeutics. PYLARIFY PSMA - Where and when. Lastly, net cash provided by operating activities was $116. NORTH BILLERICA, Mass. 8 billion tied up in biobucks. While the company generated $527M in. 6 million worth of sales while DEFINITY contributed $63. PYLARIFY injection is a fluorinated small molecule PSMA-targeted PET imaging agent that enables visualization of lymph nodes, bone and soft tissue metastases to determine the presence of recurrent and/or metastatic prostate cancer. Progenics Pharmaceuticals, Inc. , June 12, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. Lantheus Presents Results from a PYLARIFY AI™ Study at the American Urological Association (AUA) Annual Meeting. The approval covers the use of Lu177-PSMA-617 in patients who have metastatic prostate cancer that is hormone-resistant (also known as castrate-resistant) and whose tumors. 1 million for the second quarter 2022, compared to GAAP net loss of $26. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging. Lantheus Announces Presentations Featuring PYLARIFY AI at the 2023 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting June 12, 2023 BEDFORD, Mass. , a Lantheus company. 2 million and $935. Image source: The Motley Fool. February 10, 2022 17:33 ET | Source: Lantheus Holdings, Inc. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; TechneLite ® (Technetium Tc99m Generator), a. Paul joined Lantheus in 2020 and has been an exemplary leader throughout his tenure, demonstrating strong strategic and leadership skills, most notably with the very successful launch of PYLARIFY.